A new cervical cancer treatment is showing promise in boosting survival rates and reducing recurrence What this breakthrough means for patients.
Cervical cancer is the fourth most common cancer among women worldwide. In India, where it is the second most common, it ...
Dominique Johnson, who had worked for the Internal Revenue Service for 15 years, died on Jan. 30 at the age of 40 after an ...
The following is a summary of "Oncological outcomes after vaginal and robotic-assisted radical trachelectomy in patients with cervical cancer - A single-center prospective cohort study," published in ...
Cervical cancer is caused by human papillomavirus HPV and has become a major health concern Read this article to know ...
Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...
Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...
News Medical on MSN9d
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancerRegeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback